Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Therapeutic Efficacy of a Subunit Vaccine in Controlling Chronic Trypanosoma cruzi Infection and Chagas Disease Is Enhanced by Glutathione Peroxidase Over-Expression

  • Shivali Gupta ,

    shivali.04@gmail.com (SG); nigarg@utmb.edu (NG)

    Affiliation Department of Microbiology and Immunology, School of Medicine, University of Texas Medical Branch, Galveston, Texas, United States of America

  • Charity Smith,

    Affiliation Department of Microbiology and Immunology, School of Medicine, University of Texas Medical Branch, Galveston, Texas, United States of America

  • Sarah Auclair,

    Affiliation Department of Microbiology and Immunology, School of Medicine, University of Texas Medical Branch, Galveston, Texas, United States of America

  • Anahi De Jesus Delgadillo,

    Affiliation Department of Microbiology and Immunology, School of Medicine, University of Texas Medical Branch, Galveston, Texas, United States of America

  • Nisha Jain Garg

    shivali.04@gmail.com (SG); nigarg@utmb.edu (NG)

    Affiliations Department of Microbiology and Immunology, School of Medicine, University of Texas Medical Branch, Galveston, Texas, United States of America, Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America, Institute for Human Infections and Immunity and the Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Galveston, Texas, United States of America

Therapeutic Efficacy of a Subunit Vaccine in Controlling Chronic Trypanosoma cruzi Infection and Chagas Disease Is Enhanced by Glutathione Peroxidase Over-Expression

  • Shivali Gupta, 
  • Charity Smith, 
  • Sarah Auclair, 
  • Anahi De Jesus Delgadillo, 
  • Nisha Jain Garg
PLOS
x

Abstract

Trypanosoma cruzi-induced oxidative and inflammatory responses are implicated in chagasic cardiomyopathy. In this study, we examined the therapeutic utility of a subunit vaccine against T. cruzi and determined if glutathione peroxidase (GPx1, antioxidant) protects the heart from chagasic pathogenesis. C57BL/6 mice (wild-type (WT) and GPx1 transgenic (GPxtg) were infected with T. cruzi and at 45 days post-infection (dpi), immunized with TcG2/TcG4 vaccine delivered by a DNA-prime/Protein-boost (D/P) approach. The plasma and tissue-sections were analyzed on 150 dpi for parasite burden, inflammatory and oxidative stress markers, inflammatory infiltrate and fibrosis. WT mice infected with T. cruzi had significantly more blood and tissue parasite burden compared with infected/GPxtg mice (n = 5-8, p<0.01). Therapeutic vaccination provided >15-fold reduction in blood and tissue parasites in both WT and GPxtg mice. The increase in plasma levels of myeloperoxidase (MPO, 24.7%) and nitrite (iNOS activity, 45%) was associated with myocardial increase in oxidant levels (3-4-fold) and non-responsive antioxidant status in chagasic/WT mice; and these responses were not controlled after vaccination (n = 5-7). The GPxtg mice were better equipped than the WT mice in controlling T. cruzi-induced inflammatory and oxidative stress markers. Extensive myocardial and skeletal tissue inflammation noted in chagasic/WT mice, was significantly more compared with chagasic/GPxtg mice (n = 4-6, p<0.05). Vaccination was equally effective in reducing the chronic inflammatory infiltrate in the heart and skeletal tissue of infected WT and GPxtg mice (n = 6, p<0.05). Hypertrophy (increased BNP and ANP mRNA) and fibrosis (increased collagen) of the heart were extensively present in chronically-infected WT and GPxtg mice and notably decreased after therapeutic vaccination. We conclude the therapeutic delivery of D/P vaccine was effective in arresting the chronic parasite persistence and chagasic pathology; and GPx1 over-expression provided additive benefits in reducing the parasite burden, inflammatory/oxidative stress and cardiac remodeling in Chagas disease.

Introduction

Chagas disease caused by Trypanosoma cruzi is endemic in Latin America and an emerging disease in the US and other developed countries. Overall prevalence of human T. cruzi infection is at ~16–18 million cases, and ~120 million people are at risk of infection [1]. Several years after infection, 30–40% of the infected individuals develop chronic cardiomyopathy with progressive irreversible tissue destruction, arrhythmia, thromboembolic events, and congestive heart failure [2], suggested to be associated with pathologic outcomes of persistence of parasite, inflammatory infiltrate, and oxidative stress in the heart [3,4].

The current knowledge on protective immunity and vaccine development efforts against T. cruzi [5] and the pathologic role of oxidative stress in Chagas disease [4,6] have recently been reviewed. Briefly, effective immune response for the control of T. cruzi infection requires activation of CD4+ and CD8+ T cells secreting Th1 cytokines, phagocytic activity of macrophages, lytic antibody response, and T lymphocytes cytotoxic activity [6]. Subsequently, several antigens, antigen-delivery vehicles, and adjuvants have been tested to elicit immune protection to T. cruzi in experimental animals (reviewed in [5,79]). We employed an unbiased computational approach for the identification of potential vaccine candidates [10] and through rigorous analysis over a period of several years, demonstrated that three candidate antigens (TcG1, TcG2, TcG4) were maximally relevant for vaccine development [10,11]. Co-delivery of these antigens as a prophylactic vaccine elicited greater immunity and protection from T. cruzi infection than was noted with individual candidate antigens [1115]. Mice immunized with the DNA-prime/protein-boost vaccine constituted of TcG1, TcG2 and TcG4 were capable of controlling challenge infection as evidenced by a 90–97% decline in acute parasitemia and tissue parasite burden; and, subsequently, inflammatory infiltrate and tissue fibrosis were particularly absent in the heart and skeletal muscle of vaccinated mice [13].

We and others have reported that a pro-oxidant milieu is present in the myocardium in chronic Chagas disease [16,17]. Treatment with ROS scavengers or enhancement of the antioxidant capacity was beneficial in preventing myocardial oxidative adducts and hypertrophic responses and preserved the left ventricular function that otherwise was compromised in the chronic disease phase in experimental models [18,19]. A decline in oxidative stress in human Chagas disease patients given antioxidant supplement has also been shown [20,21]. These observations have supported the idea that the sustained oxidative stress contributes to pathologic outcome in Chagas disease.

In this study, we have sought to determine if therapeutic delivery of the vaccine along with enhancement of antioxidant status would be an effective treatment of chronic Chagas disease. C57BL/6 (wild-type (WT) and GPx1 transgenic (GPxtg) mice were infected with T. cruzi, and at the end of acute parasitemia, mice were given two-dose therapeutic vaccine, delivered by DNA-prime protein-boost (D/P) approach. We included in the therapeutic vaccine TcG2 and TcG4 antigens shown to elicit potent anti-parasite antibodies and CD8+T cell immunity [13,15]. GPx1 is a key enzyme for the cellular and mitochondrial defense against oxidative stress and it uses glutathione to reduce H2O2 and lipid peroxide [22]. Mice were harvested during chronic disease phase, and we examined whether the D/P therapeutic vaccine and/or enhanced antioxidant status were beneficial in controlling parasite persistence, chronic inflammation, and oxidative stress in chagasic disease.

Materials and Methods

Parasites and mice

T. cruzi trypomastigotes (SylvioX10/4 strain) were maintained and propagated by continuous in vitro passage in C2C12 cells. T. cruzi isolate and C2C12 cells were purchased from American Type Culture Collection (ATCC, Manassas VA). Mice over-expressing human glutathione peroxidase 1 (GPx-transgenic [GPxtg] have previously been described [23,24], and were kindly provided by Dr. R. Ann Sheldon, University of California San Francisco. The GPxtg mice (CD1 background) were back-crossed with C57BL/6 WT mice for more than ten generations to generate GPxtg mice on C57BL/6 genetic background. All animal experiments were performed according to the National Institutes of Health Guide for Care and Use of Experimental Animals. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Texas Medical Branch, Galveston (Permit number: 805029).

T. cruzi genes and generation of recombinant plasmids and proteins

Sequences for TcG2 and TcG4 (SylvioX10 isolate) have previously been submitted to Genbank (AY727915 and AY727917, respectively) [10,11]. TcG2 and TcG4 have been identified in CL Brenner sequence database, and exhibit 99–100% homology to XM_806323 and XM_816508, respectively. The cDNA for the two T. cruzi genes were cloned in eukaryotic expression plasmid pCDNA3.1 [10,11]. Plasmids encoding murine IL-12 (pcDNA3.msp35 and pcDNA3.msp40) and GM-CSF (pCMVI.GM-CSF) were previously described [11]. Recombinant plasmids were transformed into E. coli DH5-alpha competent cells, grown in L-broth containing 100-μg/ml ampicillin, and purified by anion exchange chromatography by using the Qiagen maxi prep kit (Qiagen, Chatsworth, CA).

The cDNAs for TcG2 and TcG4 were cloned in-frame with a C-terminal His-tag into a pET-22b plasmid (Novagen, Gibbstown, NJ). Plasmids were transformed in BL21 (DE3) pLysS-competent cells, and recombinant proteins purified by using the poly-histidine fusion, peptide-metal chelation chromatography system [13]. After purification, proteins were exchanged out of elution buffer by dialysis, and we validated that LPS contamination in the proteins was <1.0 EU/ml determined by toxin sensor limulus amebocyte lysate (LAL) assay kit (GenScript Inc. Piscataway, NJ). All cloned sequences were confirmed by restriction digestion and sequencing at the Biomolecular Core Facility at UTMB.

Infection and immunization

Mice (GPxtg and WT littermates, 6-8-weeks old) were infected with T. cruzi (10,000 trypomastigotes per mouse, intraperitoneal). Forty-five days later, mice were immunized with the 1st vaccine dose consisting of the TcG2- and TcG4-encoding plasmids with IL-12- and GM-CSF-expression plasmids (25-μg each plasmid DNA/mouse, intramuscularly). Twenty one days after the primary immunization, mice were given 2nd vaccine dose constituted of recombinant proteins (TcG2 and TcG4, 25 μg of each protein emulsified in 5 μg saponin/100 μl PBS/mouse, intradermally). Mice were harvested at 150 dpi corresponding to chronic phase of disease development, and blood, sera/plasma, and tissue samples stored at 4°C and -20°C.

Quantitative PCR and Real-time RT-PCR

For the measurement of parasite burden, blood DNA was isolated with a QiAamp Blood DNA mini kit (Qiagen, Chatsworth, CA). Skeletal muscle and heart tissue (50 mg) were subjected to proteinase K lysis, and total DNA was purified by phenol/chloroform extraction and ethanol precipitation. Total DNA (50 ng) was used as a template, and real-time PCR performed on an iCycler thermal cycler with SYBR Green Supermix (Bio-Rad, Hercules, CA) and Tc18SrDNA-specific oligonucleotides. Data were normalized to murine GAPDH and fold change in parasite burden (i.e. Tc18SrDNA level) calculated as 2−ΔCt, where ΔCt represents the Ct (infected)—Ct (control) [19,25].

Total RNA from tissue samples (50 mg) was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) and reverse transcribed using an iScript cDNA Synthesis Kit (Bio-Rad). First-strand cDNA was used as a template in a real-time PCR on an iCycler thermal cycler with SYBR Green Supermix (as above), and specific oligonucleotides were used for amplification of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hypertrophy markers [26]. The threshold cycle (Ct) values for the target mRNAs were normalized to GAPDH mRNA, and the relative expression level of each target gene was calculated as above.

Nitrate/nitrite content

The nitrite/nitrate content, indicative of NO production by iNOS, was monitored by the Griess reagent assay [27]. Briefly, plasma samples were diluted 1:5 with double distilled water. In 96-well plates, 50 μL plasma samples were mixed with 100 μl Griess reagent, consisting of 1% sulfanilamide in 5% phosphoric acid and 0.1% N-(1-napthyl) ethylenediamine dihydrochloride (1:1 ratio, vol/vol). After incubation for 10 min, formation of diazonium salt was monitored at 520 nm (standard curve: 2–100 μM sodium nitrite).

Myeloperoxidase (MPO)

MPO activity was determined by a dianisidine-H2O2 method, modified for 96-well plates. Briefly, plasma samples (10-μg protein) were added in triplicate to 0.53 mM o-dianisidine dihydrochloride (Sigma, St. Louis, MO) and 0.15 mM H2O2 in 50 mM potassium phosphate buffer (pH 6.0). After incubation for 5 min at room temperature, the reaction was stopped with 30% sodium azide, and the change in absorbance was measured at 460 nm (ɛ = 11,300 M−1·cm−1) [28]. Results were expressed as units of MPO/mg protein, whereby 1 unit of MPO was defined as the amount of enzyme degrading 1 n mol H2O2 per min at 25°C.

Antioxidant and oxidant levels

Heart and skeletal muscle tissue sections (50 mg) were washed with ice-cold Tris-buffered saline. Tissues were suspended in lysis buffer consisting of 50 mM Tris-HCl (pH, 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Nonidet P‐40, 2.5 mM KH2PO4, and protease inhibitor cocktail (tissue: buffer ratio, 1:10, w/v), and homogenized on ice using a Omni tissue homogenizer. Homogenates were centrifuged at 3000 g at 4°C for 10 min to remove cell debris and the homogenates were stored at −80°C [17]. Protein concentration was determined by Bio-Rad Protein Assay.

Total antioxidant capacity in tissue lysates was examined by using the Cayman Chemical Antioxidant Assay Kit (Ann Arbor, MI). Briefly, tissue homogenates (10 μg protein) were mixed in triplicate with 2,2'-azino-di-[3-ethylbenzthiazoline sulphonate] (ABTS, 150 μM) / metmyoglobin (2.5 μM) reagent, and the reaction was started with H202 (75 μM). The ability of antioxidants in the sample to inhibit the formation of ABTS•+ radical was monitored at 405 nm [29]. The capacity of the antioxidants in the sample to prevent ABTS oxidation was compared with that of Trolox, a water-soluble tocopherol analogue, and quantified as molar Trolox equivalents.

We measured advanced oxidation protein products (AOPPs) in tissue lysates by spectrophotometry [30]. Briefly, in 96-well plates, plasma samples (1:10 dilution in phosphate-buffered saline [PBS]; 200-μl/well) were mixed in triplicate with 10 μl of 1.16 M potassium iodide and 20 μl of 100% acetic acid. The formation of chloramine-T, which absorbs at 340 nm in the presence of potassium iodide, was immediately read at 340 nm using a M2 SpectraMax microplate reader (Molecular Devices, Sunnyvale, CA). A standard curve was prepared using chloramine-T (linear range, 1 to 100 μ mol, Sigma), and the AOPP concentration was expressed as μ mol chloramine-T equivalents.

Histology

Tissue sections were fixed in 10% buffered formalin for 24 h, dehydrated in absolute ethanol, cleared in xylene, and embedded in paraffin. Five-micron sections of the heart and skeletal muscle tissue (≥ 3 tissue sections/organ/mouse, n = 4–6) were stained with hematoxylin/eosin (H&E) and Masson’s Trichrome [20] to examine inflammatory infiltrate/myocarditis and collagen deposition, respectively. Each tissue-section was analyzed for >10-microscopic fields (100 X magnifications) by two investigators who were blinded to identity of the experimental groups. Myocarditis (presence of inflammatory cells) from H&E stained sections was scored as 0 (absent), 1 (focal or mild, 0–1 foci), 2 (moderate, ≥2 foci), 3 (extensive inflammatory foci, minimal necrosis, and retention of tissue integrity), and 4 (diffused inflammation with severe tissue necrosis, interstitial edema, and loss of integrity) [26]. Inflammatory infiltrates were characterized as diffused or focal depending upon how closely the inflammatory cells were associated. The parasitic foci in skeletal muscle and heart tissue sections were scored as (0) absent, (1) 0–1 foci, (2) 1–5 foci, and (3)>5 foci. Cardiac fibrosis was assessed by measuring the Masson’s Trichrome-stained collagen area as a percentage of the total myocardial area using Simple PCI software (version 6.0; Compix, Sewickley, PA) connected to an Olympus polarizing microscope system (Center Valley, PA). All pixels with blue stain in Masson’s trichrome-stained sections were selected to build a binary image, subsequently calculating the total area occupied by connective tissue. Sections were categorized based on % fibrotic area: (0) <1%, (1) 1–5%, (2) 5–10%, (3) 10–15%, and (4) >15%.

Statistical analysis

All experiments were conducted with triplicate observations per sample (n = 4–8 mice/group), and data are expressed as mean ± standard deviation (SD). All data were analyzed using InStat version 3 (GraphPad, La Jolla, CA), SPSS version14.0 (SPSS Inc., Chicago, IL), or SigmaPlot version 13.0 (Systat Software, San Jose, CA). Normally distributed data were analyzed by the Student’s t test (for comparison of 2 groups) and one-way analysis of variance (ANOVA) with Tukey's post hoc test (for comparison of multiple groups). Data sets that were found not to be normally distributed were analyzed with the Kruskal-Wallis test followed by the Mann-Whitney test to assess the differences between pair-wise comparisons. Significance is presented as #,*p <0.05 and ##,**p <0.01 (*,**wild-type-versus-GPxtg; #,##normal-versus-infected, or infected-versus-infected/vaccinated).

Results

C57BL/6 wild‐type mice infected with 10,000 parasites exhibit peak parasitemia during 14–45 dpi, and develop chronic disease by ~120 dpi [15,25]. We employed this well‐established experimental model to examine the therapeutic efficacy of a 2-component D/P vaccine in controlling parasite persistence and chronic disease. Further, we included GPx1tg mice in the study to determine if enhancing the cellular antioxidant status would alter the host’s resistance against chronic Chagas disease.

All mice, irrespective of the antioxidant status were infected by T. cruzi, evidenced by an increase in blood and tissue parasite burden (Fig 1). Therapeutic delivery of vaccine resulted in 14.7-fold and 29.5-fold decline in blood and skeletal muscle levels of Tc18SrDNA levels, respectively, in chronically-infected/vaccinated WT mice when compared to that noted in chagasic/non-vaccinated WT mice (Fig 1A & 1B, all #p<0.05–0.01). Interestingly, chronically-infected GPxtg mice exhibited 2.4–2.7-fold and 5.6-8-fold lower level of blood and skeletal tissue parasite burden, respectively, than was noted in infected/WT mice before as well as after therapeutic vaccine delivery (Fig 1A & 1B, **p<0.01). A similar decline in heart tissue parasite burden (4.2-fold) was observed in response to therapeutic vaccine in chronically-infected WT and GPxtg mice (Fig 1C, ##p<0.01). Together, these data suggested that a) therapeutic D/P vaccine was efficacious in arresting parasite persistence in chagasic mice, and b) GPxtg mice were better equipped than the WT litter-mates in controlling T. cruzi that resulted in enhanced efficacy of the therapeutic vaccine.

thumbnail
Fig 1. Control of T. cruzi persistence by a therapeutic vaccine in GPx-transgenic and wild-type mice.

Glutathione peroxidase 1 over-expressing (GPx-transgenic, GPxtg) mice and wild-type (WT) littermates were infected with T. cruzi trypomastigotes (10,000 parasites/mouse), and immunized with a two-component DNA-prime/protein boost (D/P) vaccine (1st dose: TcG2- and TcG4-encoding plasmids + IL-12- and GMCSF-expression plasmids at 45 days post-infection (pi); and 2nd dose: recombinant TcG2 and TcG4 proteins at 66 days pi), as detailed in Materials and Methods. Mice were harvested at 150 days pi corresponding to the chronic disease phase. Total DNA isolated from blood (A), skeletal muscle (B) and heart (C) of the infected/vaccinated and infected/non-vaccinated mice were subjected to quantitative real time PCR amplification for Tc18SrDNA sequence. Bar graphs show the Tc18SrDNA level normalized to murine GAPDH gene. In all figures, data are expressed as mean ± SD, and significance is presented as #,*P < 0.05 and ##,**P < 0.01 (* wild-type versus GPxtg; # wild-type versus infected, or infected versus infected/vaccinated).

https://doi.org/10.1371/journal.pone.0130562.g001

Oxidative and inflammatory stresses are known to be of pathologic significance in Chagas disease [6,31]. We evaluated plasma levels of MPO activity and nitrite content and myocardial antioxidant status to gain a quantitative measure of vaccine efficacy in controlling chronic stress in chagasic mice. The chronically-infected WT mice showed a 24.7% increase in plasma levels of MPO activity that was not significantly controlled after therapeutic vaccine delivery (Fig 2A, p<0.05–0.01). The GPxtg mice exhibited a lower basal plasma level of MPO activity than was noted in WT mice. The MPO activity was only marginally increased post-infection (12% increase) and normalized to control level after vaccination in GPxtg mice (Fig 2A). The plasma nitrite levels were increased by 45% and 39% in chronically-infected WT and GPxtg mice, respectively, and remained high after therapeutic vaccination (Fig 2B). The basal level of oxidants (data not shown) and antioxidants (Fig 2C) were not different in WT and GPxtg mice. In response to chronic infection, WT mice exhibited 3–4‐fold increase in myocardial oxidants, yet no increase in antioxidant levels was observed after infection or after vaccination-dependent control of chronic parasite persistence (Fig 2C). In comparison, GPxtg mice exhibited significantly lower level of oxidative stress associated with >2-fold increase in antioxidant status during chronic infection when compared to that noted in chagasic WT mice (Fig 2C, **p<0.01). Therapeutic vaccination of chronically-infected GPxtg mice was particularly effective and resulted in normal basal levels of myocardial oxidant (data not shown) and antioxidant status (Fig 2C). Together, the results presented in Fig 2 suggested that macrophage (NOS2/•NO) and neutrophil (MPO) activation contribute to chronic inflammatory state in chagasic mice and these responses were not subdued by therapeutic vaccine delivery. MPO, produced by activated neutrophils that use H2O2 and chloride to produce reactive hypochlorous acid, was not activated in chronically-infected GPx1tg mice. Further, therapeutic vaccine mediated control of persisting T. cruzi did not prevent the antioxidant/oxidant imbalance in chagasic WT mice. However, the enhanced cellular antioxidant capacity in GPxtg mice was beneficial in preventing myocardial oxidative stress caused by chronic T. cruzi infection.

thumbnail
Fig 2. Inflammatory and antioxidant state in GPxtg and WT mice during chronic Chagas disease (± therapeutic vaccine).

Mice (GPxtg and WT) were infected, vaccinated and harvested during chronic disease phase as in Fig 1. (A) Myeloperoxidase (MPO) activity in plasma by dianisidine-H2O2 method. (B) Nitrite content in reduced plasma samples, an indicator of inducible nitric oxide synthase (iNOS) activity, was determined by Griess reagent assay. (C) Total antioxidant capacity in heart homogenates of infected and infected/vaccinated mice was determined as detailed in Materials and Methods.

https://doi.org/10.1371/journal.pone.0130562.g002

Next, we determined the effects of therapeutic vaccine (± GPx over-expression) on T cruzi–induced myocarditis. Histological studies showed pronounced inflammatory infiltrate with diffused inflammatory foci in heart (score: 1–4, average: 2.3, Fig 3A.c) and skeletal muscle (score: 1–3, average: 2, Fig 4A.c) of chronically-infected WT mice. Myocardial degeneration with enlarged myocytes was particularly evident in chagasic WT mice. Therapeutic vaccination resulted in a substantial decline in myocardial (score: 0–2, average: 0.75, Fig 3A.e) and skeletal muscle (range: 0–3, average: 1.125, Fig 4A.e) levels of inflammatory infiltrate in chagasic WT mice. In comparison, chronically-infected GPxtg mice presented a lower level of inflammatory infiltrate in heart (score: 0–3, average: 0.89, Fig 3A.d) and skeletal muscle (score: 0–2, average: 0.875, Fig 4A.d) that was further controlled after therapeutic vaccination (Fig 3A.f & Fig 4A.f). Together, the data presented in Figs 3 & 4 suggested that GPxtg mice were better equipped than the WT mice in preventing the T. cruzi-induced inflammation of the heart, and therapeutic vaccination was effective in arresting the chronic infiltration of the inflammatory infiltrate in the heart in chagasic mice.

thumbnail
Fig 3. Myocardial inflammatory infiltrate in GPxtg and WT mice during chronic Chagas disease (± therapeutic vaccine).

Mice (GPxtg and WT) were infected, vaccinated, and harvested during chronic disease phase as in Fig 1. (A) Paraffin-embedded left ventricular (LV) heart sections (5 μm) were examined by hematoxylin/eosin (H&E) staining (blue: nuclear; pink: muscle/cytoplasm). Shown are representative H&E images of tissue sections from normal (a&b), infected (c&d), and infected/vaccinated (e&f) mice harvested during chronic disease phase (>150 days post-infection, magnification: 20X). (B) The inflammatory score (myocarditis) were derived from two different experiments (n = 4 mice per group per experiment) as described in the Materials and Methods section.

https://doi.org/10.1371/journal.pone.0130562.g003

thumbnail
Fig 4. Chronic inflammation in skeletal muscle of GPxtg and WT chagasic mice (± therapeutic vaccine).

GPxtg and WT mice were infected with T. cruzi and immunized with the two-component D/P vaccine as in Fig 1. Paraffin-embedded skeletal muscle sections (5 μm) were examined by hematoxylin/eosin (H&E) staining Shown are representative H&E images of tissue sections from normal (a&b), infected (c&d), and infected/vaccinated (e&f) mice harvested during chronic disease phase (>150 days post-infection, magnification: 20X). (B) The inflammatory score were derived from two different experiments (n = 4 mice per group per experiment).

https://doi.org/10.1371/journal.pone.0130562.g004

ROS and inflammatory mediators have been suggested to promote the development of interstitial and perivascular fibrosis, as well as myocardial hypertrophy. Histological staining with Masson's Trichrome of the tissue sections detected a high degree of myocardial remodeling associated with a significant disruption of cardiomyocytes in chronically-infected WT and GPxtg mice (Fig 5). Semi-quantitative measurements of collagen area (blue, 3 regions per heart, n ≥ 4) suggested the fibrotic area, specifically around the vasculature, was significantly increased in chagasic WT (1.28–13.06%, average 6.65%) and GPxtg (3.09–16.52%, average 7.42%) mice when compared to that noted in normal mice (compare Fig 5A.a&b with Fig 5A.c&d, p<0.01). The increase in collagen deposition was associated with up to 50% increase in mRNA levels for ANP and/or BNP hypertrophy markers in the myocardium of chronically infected WT and GPxtg mice (*p < 0.01). Therapeutic vaccination resulted in a notable decline in myocardial collagen area in WT (0.29–4.79%, average 1.39%) and GPxtg (0.486–3.658%, average 1.87%) chagasic mice (compare Fig 5A.c&d with Fig 5A.e&f). These data suggested that therapeutic vaccination was beneficial in controlling the chronic evolution of hypertrophic and fibrotic responses in chagasic mice, and GPx1tg mice may be marginally better in preventing the chagasic cardiac remodeling.

thumbnail
Fig 5. Cardiac fibrosis is controlled in GPx transgenic mice (± therapeutic vaccine).

Mice (GPxtg and WT) were infected and vaccinated as in Fig 1. Paraffin-embedded left ventricular (LV) heart sections (5 μm) were examined by Masson’s trichrome staining. Shown are representative images (collagen fibers: blue, nuclei: black, background: red) of tissue sections from normal (a&b), infected (c&d), and infected/vaccinated (e&f) mice harvested during chronic disease phase (>150 days post-infection, magnification: 20X). (B) The fibrosis score was derived from two different experiments (n = 4 mice per group per experiment), and was calculated as described in Materials and Methods section.

https://doi.org/10.1371/journal.pone.0130562.g005

Discussion

Before setting the goal of new therapy development, an important question is whether it will fill gaps in achieving health benefits and if it will be an economically viable approach. Several studies, including our published reports (reviewed in [5]), have shown the prophylactic subunit vaccine mediated control of infection and disease in experimental models generally resembles that noted in the 60–70% of the chagasic patients that remain seropositive and maintain residual parasites for their entire lives, but do not develop a clinically symptomatic form of the disease [3]. In terms of treatment, acutely-infected patients, irrespective of their ages, are shown to respond to treatment with the anti-parasite drug benznidazole and be cured, defined by the control of acute parasitemia and myocarditis [32]. However, benznidazole and nifurtimox (anti-trypanosomal drugs) have not shown efficacy in the treatment of indeterminate status or chagasic cardiomyopathy [33]. The intolerance and unacceptable side effects in 30–50% of the treated individuals [34], mutagenic properties, and contra-indication in pregnancy have restricted the use of these drugs as a standard therapy in chagasic patients [35]. An effective therapeutic vaccine for human Chagas disease could prevent cardiac complications among the estimated 40,000 new cases of Chagas disease that occur in Latin America annually, avert over 600,000 DALYs annually that result from cardiomyopathy and gastrointestinal disease, and prevent 10,000 deaths or more annually [36]. Computer simulation modeling studies suggest that even when the risk of infection is only 1% and protective efficacy is only 25%, a vaccine would be economically viable and beneficial as long as the cost is US$20 or lower per vaccine dose [37]. The potential savings in term of cost of treatment per patient-year are estimated to be US$1028, with lifetime costs averaging US$11,619 per patient [38]. Thus, we believe that vaccination to reduce the frequency and severity of clinical disease by decreasing the extent of persistent parasite burden is urgently needed to improve the health outcomes in chagasic patients; and continuing efforts towards developing a prophylactic and therapeutic vaccine against T. cruzi infection and Chagas disease are economically justifiable.

Based upon several studies that we have conducted, we believe TcG2 and TcG4 candidate antigens are an excellent choice for therapeutic vaccine development, and a heterologous prime/boost approach for vaccine delivery is highly efficacious against T. cruzi and Chagas disease. The selected candidates TcG2 and TcG4 tested in this study are highly conserved in clinically relevant T. cruzi strains, and expressed (mRNA/protein) in infective trypomastigote and intracellular amastigote stages of T. cruzi [10]. We have shown the delivery of candidate antigens as a DNA-prime/protein-boost or DNA-prime/MVA-boost preventative vaccine was highly effective in generating protective immunity consisting of parasite- and antigen-specific lytic antibodies and type 1 CD8+ cytotoxic T lymphocytes against challenge infection and chronic disease in mice [14,15]. The enhanced efficacy of a heterologous prime/boost approach for vaccine delivery could be because delivery of antigens as DNA vaccine elicits robust T-cell responses, which are critical for the development of T-cell-dependent antibody responses [39,40]. Delivery of vaccine candidates as recombinant proteins is generally more effective at eliciting antibody responses and may directly stimulate antigen-specific memory B cells to differentiate into antibody-secreting cells, resulting in production of high-titer, antigen-specific antibodies [41,42]. Therefore, DNA-prime plus protein-boost is a complementary approach that overcomes each of their respective shortcomings. This, to the best of our knowledge, is the first study demonstrating the therapeutic efficacy of a subunit vaccine delivered by a DNA-prime/protein-boost approach in arresting T. cruzi persistence and chagasic disease in a murine model. We vaccinated mice during the indeterminate state when, similar to humans, the acute parasitemia was controlled and clinical disease symptoms have not yet developed. A majority of human patients are generally identified during this phase to be seropositive and carrying T. cruzi infection. Importantly, therapeutic delivery of TcG2/TcG4-encoding DNA-prime/protein-boost vaccine arrested the progression to chronic disease phase, evidenced by up to 10-fold control of peripheral and tissue levels of parasite burden as determined by a highly sensitive qPCR approach (Fig 1), and a significant decline in tissue infiltration of inflammatory infiltrate (Figs 3 & 4), and cardiac remodeling (Fig 5) that were otherwise pronounced in WT infected/non-vaccinated chagasic mice. Others have shown that immunotherapy with a Tc24- or TSA1-encoding DNA vaccine immediately after lethal infection led to survival of >70% of mice [43] and when given after acute parasitemia led to reduced cardiac inflammation [43,44] in infected mice. We surmise that therapeutic vaccines targeting T. cruzi parasites provide a relevant approach for reducing the cardiac tissue damage in Chagas disease.

We included mice overexpressing GPx in this study to test the idea that these mice will be better equipped in controlling chagasic pathology. Our observation of a low grade inflammation and a decline in the expression of hypertrophic markers and collagen deposition in chronically-infected/GPxtg mice suggests that ROS signals inflammatory responses and hypertrophic remodeling in chagasic myocardium. Indeed, ROS is known to signal inflammatory responses in diverse disease models and both ROS and inflammatory cytokines, e.g., TNF-α, IL-1β, and MCP-1, can promote fibrosis and tissue remodeling. The treatment with an antioxidant or enhanced mitochondrial antioxidant capacity is shown to result in a significant decline in myocardial oxidative adducts concurrent with preservation of a cardiac hemodynamic state in chagasic rodents [19,45]. A decline in oxidative stress in human Chagas disease patients given Vitamin A is also shown [20]. These observations, thus, support the idea that sustained oxidative stress is of pathological importance in chagasic cardiomyopathy, and antioxidants should be considered as adjunct therapies along with anti-parasite treatments in arresting chronic chagasic pathology.

Surprisingly, we observed a decline in peripheral and tissue parasite burden in GPxtg mice with or without therapeutic vaccine delivery, suggesting that oxidative state of the host determines the quality and efficacy of immune responses in arresting parasite survival and persistence. A recent study has shown a slower increase in blood parasitemia in mice given antioxidant (vitamin C) therapy, though authors noted no significant differences in tissue levels of T. cruzi and inflammatory infiltrate in chronic disease phase [46]. GPx deficiency has been linked to mutation of coxsackie virus B3 viral genome, with replacement of G base (most vulnerable to oxidation) at three of the seven sites [47], and enhanced myocarditis in Gpx1-/- mice, though authors did not conclude enhanced viral burden. Likewise, GPX1-/- mice developed higher levels of influenza A virus induced lung inflammation but it was not associated with increased viral load [48]. Thus, our observation of a better control of parasite burden in GPxtg chagasic mice provide the first indication of a role of oxidative state of the host in eliciting appropriate immune responses. How ROS may alter host immunity in the context of T. cruzi infection and Chagas disease is not known. Besides signaling of NF-κB pathway of cytokine gene expression, ROS is suggested to enhance proliferation and activation of proinflammatory immune cells via activation of glycolytic metabolic pathways. However, over-production of ROS can alter the function of immune cells by direct oxidative damage or oxidative inhibition of transcription factors and cell-surface receptors involved in activation of adaptive immunity. Future studies delineating the kinetics of ROS signaling of metabolic pathways for altering the pro-inflammatory function of immune cells will help design novel strategies for achieving pathogen control [49,50] versus controlling chronic inflammatory state as is suitable for diverse heart diseases.

In summary, we have shown the therapeutic utility of a subunit vaccine against T. cruzi demonstrated in WT and GPxtg mice. Our data showed that therapeutic vaccination provided >15-fold reduction in blood and tissue parasites, and subsequently, chronic myocarditis was controlled in mice receiving therapeutic vaccine. The Gpxtg mice were better equipped than the WT mice in arresting the chronic parasite persistence, inflammatory/oxidative stress and cardiac remodeling in Chagas disease.

Author Contributions

Conceived and designed the experiments: NG SG. Performed the experiments: SG AD CS SA. Analyzed the data: SG AD CS SA NG. Contributed reagents/materials/analysis tools: NG. Wrote the paper: NG SG SA.

References

  1. 1. World Health Organization (2010) Chagas disease: control and elimination. UNDP/World Bank/WHO, http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_17-en.pdf (accessed Jan 30 2015).
  2. 2. Rassi A Jr., Rassi A, Marin-Neto JA (2010) Chagas disease. Lancet 375: 1388–1402. pmid:20399979
  3. 3. Cunha-Neto E, Chevillard C (2014) Chagas disease cardiomyopathy: immunopathology and genetics. Mediators Inflamm 2014: 683230. pmid:25210230
  4. 4. Nagajyothi F, Machado FS, Burleigh BA, Jelicks LA, Scherer PE, Mukherjee S et al. (2012) Mechanisms of Trypanosoma cruzi persistence in Chagas disease. Cell Micr,obiol 14: 634–643.
  5. 5. Vázquez-Chagoyán JC, Gupta S, Garg NJ (2011) Vaccine development against Trypanosoma cruzi and Chagas disease. Advanced parasitol 75: 121–146. pmid:21820554
  6. 6. Machado FS, Dutra WO, Esper L, Gollob KJ, Teixeira MM, Factor SM, et al. (2012) Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Seminars in Immunopathology 34: 753–770. pmid:23076807
  7. 7. Bhatia V, Garg NJ (2005) Current status and future prospects for a vaccine against American trypanosomiasis. Expert Rev Vaccines 4: 867–880. pmid:16372882
  8. 8. Bhatia V, Wen J-J, Zacks MA, Garg NJ (2009) American trypanosomiasis and perspectives on vaccine development. In: Stanberry LR, Barrett AD, editors. Vaccines for Biodefense and Emerging and Neglected Diseases. New York: Academic Press. pp. 1407–1434.
  9. 9. Quijano-Hernandez I, Dumonteil E (2011) Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin 7: 1184–1191. pmid:22048121
  10. 10. Bhatia V, Sinha M, Luxon B, Garg NJ (2004) Utility of Trypanosoma cruzi sequence database for the identification of potential vaccine candidates: In silico and in vitro screening. Infect Immun 72: 6245–6254. pmid:15501750
  11. 11. Bhatia V, Garg NJ (2008) Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin Vaccine Immunol 15: 1158–1164. pmid:18550728
  12. 12. Aparicio-Burgos JE, Ochoa-Garcia L, Zepeda-Escobar JA, Gupta S, Dhiman M, Martínez JS, et al. (2011) Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs. PLoS Negl Trop Dis 5: e1050. pmid:21625470
  13. 13. Gupta S, Garg NJ (2010) Prophylactic efficacy of TcVac2R against Trypanosoma cruzi in mice. PLoS Negl Trop Dis 4: e797. pmid:20706586
  14. 14. Gupta S, Garg NJ (2012) Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8+T cell mediated immunity against Trypanosoma cruzi. Vaccine 12: 1464–1478
  15. 15. Gupta S, Garg NJ (2013) TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice. PLOS ONE 8: e59434. pmid:23555672
  16. 16. Wen JJ, Dhiman M, Whorton EB, Garg NJ (2008) Tissue-specific oxidative imbalance and mitochondrial dysfunction during Trypanosoma cruzi infection in mice. Microbes Infect 10: 1201–1209. pmid:18675934
  17. 17. Wen J-J, Vyatkina G, Garg NJ (2004) Oxidative damage during chagasic cardiomyopathy development: Role of mitochondrial oxidant release and inefficient antioxidant defense. Free Radic Biol Med 37: 1821–1833. pmid:15528041
  18. 18. Dhiman M, Wan X-X, PL V, Vargas G, Garg NJ (2013) MnSODtg mice control myocardial inflammatory and oxidative stress and remodeling responses elicited in chronic Chagas disease. J Am Heart Assoc 2: e000302. pmid:24136392
  19. 19. Wen J-J, Gupta S, Guan Z, Dhiman M, Condon D, et al. (2010) Phenyl-alpha-tert-butyl-nitrone and benzonidazole treatment controlled the mitochondrial oxidative stress and evolution of cardiomyopathy in chronic chagasic rats. J Am Coll Cardiol 55: 2499–2508. pmid:20510218
  20. 20. Macao LB, Filho DW, Pedrosa RC, Pereira A, Backes P, Torres MA, et al. (2007) Antioxidant therapy attenuates oxidative stress in chronic cardiopathy associated with Chagas' disease. Int J Cardiol 123: 43–49. pmid:17328977
  21. 21. Barbosa JL, Thiers CA, de Braganca Pereira B, do Nascimento EM, Ribeiro Frazon CM, Budni P, et al. (2014) Impact of the use of benznidazole followed by antioxidant supplementation in the prevalence of ventricular arrhythmias in patients with chronic Chagas disease: Pilot Study. Am J Ther. Epub ahead of print.
  22. 22. Halliwell B (1999) Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 31: 261–272. pmid:10517532
  23. 23. Sheldon RA, Christen S, Ferriero DM (2008) Genetic and pharmacologic manipulation of oxidative stress after neonatal hypoxia-ischemia. Int J Dev Neurosci 26: 87–92. pmid:17935927
  24. 24. Sheldon RA, Aminoff A, Lee CL, Christen S, Ferriero DM (2007) Hypoxic preconditioning reverses protection after neonatal hypoxia-ischemia in glutathione peroxidase transgenic murine brain. Pediatr Res 61: 666–670. pmid:17426643
  25. 25. Garg NJ, Bhatia V, Gerstner A, deFord J, Papaconstantinou J (2004) Gene expression analysis in mitochondria from chagasic mice: Alterations in specific metabolic pathways. Biochemical J 381: 743–752. pmid:15101819
  26. 26. Dhiman M, Garg NJ (2011) NADPH oxidase inhibition ameliorates Trypanosoma cruzi-induced myocarditis during Chagas disease. J Pathol 225: 583–596. pmid:21952987
  27. 27. Kleinbongard P, Rassaf T, Dejam A, Kerber S, Kelm M (2002) Griess method for nitrite measurement of aqueous and protein-containing samples. Methods Enzymol 359: 158–168. pmid:12481568
  28. 28. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206–209. pmid:6276474
  29. 29. Miller NJ, Rice-Evans C, Davies MJ (1993) A new method for measuring antioxidant activity. Biochem Soc Trans 21: 95S. pmid:8359548
  30. 30. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Canteloup S, et al. (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304–1313. pmid:8731095
  31. 31. Gupta S, Wen JJ, Garg NJ (2009) Oxidative Stress in Chagas Disease. Interdiscip Perspect Infect Dis 2009: 190354. pmid:19547716
  32. 32. Caldas IS, Talvani A, Caldas S, Carneiro CM, de Lana M, da Matta Guedes PM, et al. (2008) Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol Res 103: 413–421. pmid:18454349
  33. 33. Pinazo MJ, Guerrero L, Posada E, Rodriguez E, Soy D, Gascon J (2013) Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. Antimicrob Agents Chemother 57: 390–395. pmid:23114763
  34. 34. Pinazo MJ, Munoz J, Posada E, Lopez-Chejade P, Gallego M, Ayala E, et al. (2010) Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 54: 4896–4899. pmid:20823286
  35. 35. Bern C (2011) Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 364: 2527–2534. pmid:21714649
  36. 36. Lescure FX, Le Loup G, Freilij H, Develoux M, Paris L, Brutus L, et al. (2010) Chagas disease: changes in knowledge and management. Lancet Infect Dis 10: 556–570. pmid:20670903
  37. 37. Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR (2010) The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. PLoS Negl Trop Dis 4: e916. pmid:21179503
  38. 38. Castillo-Riquelme M, Guhl F, Turriago B, Pinto N, Rosas F, Martinez MF, et al. (2008) The costs of preventing and treating chagas disease in Colombia. PLoS Negl Trop Dis 2: e336. pmid:19015725
  39. 39. Huygen K (2005) Plasmid DNA vaccination. Microbes Infect 7: 932–938. pmid:15878683
  40. 40. Donnelly JJ, Wahren B, Liu MA (2005) DNA vaccines: progress and challenges. J Immunol 175: 633–639. pmid:16002657
  41. 41. Scharpe J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, Claes K, et al. (2009) Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis 54: 77–85. pmid:19339089
  42. 42. Zeng R, Zhang Z, Mei X, Gong W, Wei L (2008) Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice. Biochem Biophys Res Commun 377: 495–499. pmid:18851947
  43. 43. Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Arjona-Torres A, Ramirez-Sierra MJ (2004) Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect Immun 72: 46–53. pmid:14688079
  44. 44. Zapata-Estrella H, Hummel-Newell C, Sanchez-Burgos G, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A, et al. (2006) Control of Trypanosoma cruzi infection and changes in T-cell populations induced by a therapeutic DNA vaccine in mice. Immunol Lett 103: 186–191. pmid:16378645
  45. 45. Wen J-J, Bhatia V, Popov VL, Garg NJ (2006) Phenyl-alpha-tert-butyl nitrone reverses mitochondrial decay in acute Chagas disease. Am J Pathol 169: 1953–1964. pmid:17148660
  46. 46. Gusmao AS, Castanho RE, Andrade RF, Farsetti CM, Mathias AB, Therezo AL, et al. (2012) Vitamin C effects in mice experimentally infected with Trypanosoma cruzi QM2 strain. Rev Soc Bras Med Trop 45: 51–54. pmid:22370828
  47. 47. Beck MA, Esworthy RS, Ho YS, Chu FF (1998) Glutathione peroxidase protects mice from viral-induced myocarditis. FASEB J 12: 1143–1149. pmid:9737717
  48. 48. Yatmaz S, Seow HJ, Gualano RC, Wong ZX, Stambas J, Selemidis S, et al. (2013) Glutathione peroxidase-1 reduces influenza A virus-induced lung inflammation. Am J Respir Cell Mol Biol 48: 17–26. pmid:23002098
  49. 49. Dreesen L, De Bosscher K, Grit G, Staels B, Lubberts E, Bauge E, et al. (2014) Giardia muris infection in mice is associated with a protective interleukin 17A response and induction of peroxisome proliferator-activated receptor alpha. Infect Immun 82: 3333–3340. pmid:24866800
  50. 50. Carvalho MD, Alonso DP, Vendrame CM, Costa DL, Costa CH, Werneck GL, et al. (2014) Lipoprotein lipase and PPAR alpha gene polymorphisms, increased very-low-density lipoprotein levels, and decreased high-density lipoprotein levels as risk markers for the development of visceral leishmaniasis by Leishmania infantum. Mediators Inflamm 2014: 230129. pmid:25242866